Skip to content
MedsAcross

Medicine

Buprenorphine 8 mg sublingual tablet

Buprenorphine · Sublingual
Available on requestPrescription onlyUS FDAControlled, schedule CIIIGeneric name

Buprenorphine 8 mg sublingual tablet is a generic prescription medicine for sublingual use, made by 18 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

and Disposal Because of the risks associated with accidental ingestion…

Key facts

Active ingredient (INN)
Buprenorphine
Brand
Sold under the generic name
Strength
8 mg
Dosage form
Sublingual tablet
Route
Sublingual
Packs
30 tablets, 3 blister pack, 90 tablets and 61 more
Manufacturers
Sun Pharmaceutical IndustriesIndiaCamber PharmaceuticalsIndiaBryant Ranch PrepackAdvagen PharmaActavis PharmaHikma PharmaceuticalsPAI PharmaRhodes PharmaceuticalsSpecGx18 labelers on the register
Origin register
US FDA, United States
Storage
and Disposal Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store Buprenorphine Sublingual Tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Schedule CIII
ATC code
N02AE01 Buprenorphine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
8 October 2009
Identifiers
RxCUI 351264, 351265, 2747481 +1DailyMed set ID 699638dd-3a53-445f-a545-d0e6eabfe1c9, 3a7418a2-bd6e-4082-b0fe-a5498e7b944a, 1bf8b35a-b769-465c-a2f8-099868dfcd2f +22NDC 72888-183, 58118-0177, 0054-0177 +22Application ANDA090279, ANDA078633, ANDA201760 +5

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

A sample of 40 packs from 18 labelers. The register lists 64 packs for this generic presentation, and we confirm the exact pack on the quote.

PackCodeLabelerMarketed since
30 tablet in 1 bottle31722-871-30Camber PharmaceuticalsIndia12 January 2026
3 blister pack in 1 carton / 10 tablet in 1 blister pack62756-460-64Sun Pharmaceutical IndustriesIndia17 February 2016
30 tablet in 1 bottle62756-460-83Sun Pharmaceutical IndustriesIndia17 February 2016
30 tablet in 1 bottle0228-3153-03Actavis Pharma10 April 2015
30 tablet in 1 bottle72888-183-30Advagen Pharma23 January 2024
90 tablet in 1 bottle72888-183-90Advagen Pharma23 January 2024
30 tablet in 1 bottle0054-0177-13Hikma Pharmaceuticals8 October 2009
30 tablet in 1 bottle0121-2038-30PAI Pharma12 October 2023
30 tablet in 1 bottle42858-502-03Rhodes Pharmaceuticals25 October 2017
30 tablet in 1 bottle0406-7018-03SpecGx19 January 2026
120 tablet in 1 bottle71335-1154-0Bryant Ranch Prepack3 April 2024
90 tablet in 1 bottle71335-1154-1Bryant Ranch Prepack15 March 2019
60 tablet in 1 bottle71335-1154-2Bryant Ranch Prepack15 March 2019
30 tablet in 1 bottle71335-1154-3Bryant Ranch Prepack22 July 2019
20 tablet in 1 bottle71335-1154-4Bryant Ranch Prepack3 April 2024
7 tablet in 1 bottle71335-1154-5Bryant Ranch Prepack16 January 2020
28 tablet in 1 bottle71335-1154-6Bryant Ranch Prepack28 June 2021
1 tablet in 1 bottle71335-1154-7Bryant Ranch Prepack3 April 2024
12 tablet in 1 bottle71335-1154-8Bryant Ranch Prepack3 April 2024
14 tablet in 1 bottle71335-1154-9Bryant Ranch Prepack3 April 2024
120 tablet in 1 bottle71335-1163-0Bryant Ranch Prepack17 May 2024
90 tablet in 1 bottle71335-1163-1Bryant Ranch Prepack21 March 2019
60 tablet in 1 bottle71335-1163-2Bryant Ranch Prepack24 April 2019
30 tablet in 1 bottle71335-1163-3Bryant Ranch Prepack1 April 2019
20 tablet in 1 bottle71335-1163-4Bryant Ranch Prepack17 May 2024
7 tablet in 1 bottle71335-1163-5Bryant Ranch Prepack17 May 2024
28 tablet in 1 bottle71335-1163-6Bryant Ranch Prepack17 May 2024
1 tablet in 1 bottle71335-1163-7Bryant Ranch Prepack17 May 2024
12 tablet in 1 bottle71335-1163-8Bryant Ranch Prepack17 May 2024
14 tablet in 1 bottle71335-1163-9Bryant Ranch Prepack17 May 2024
120 tablet in 1 bottle71335-3152-0Bryant Ranch Prepack29 June 2026
90 tablet in 1 bottle71335-3152-1Bryant Ranch Prepack29 June 2026
60 tablet in 1 bottle71335-3152-2Bryant Ranch Prepack29 June 2026
30 tablet in 1 bottle71335-3152-3Bryant Ranch Prepack29 June 2026
20 tablet in 1 bottle71335-3152-4Bryant Ranch Prepack29 June 2026
7 tablet in 1 bottle71335-3152-5Bryant Ranch Prepack29 June 2026
28 tablet in 1 bottle71335-3152-6Bryant Ranch Prepack29 June 2026
1 tablet in 1 bottle71335-3152-7Bryant Ranch Prepack29 June 2026
12 tablet in 1 bottle71335-3152-8Bryant Ranch Prepack29 June 2026
14 tablet in 1 bottle71335-3152-9Bryant Ranch Prepack29 June 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 29 December 1981Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Buprenorphine

Clinical summary

Buprenorphine is a partial opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids, among other approved uses. MedsAcross supplies Buprenorphine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Buprenorphine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Buprenorphine 8 mg sublingual tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.